An experimental inflammatory bowel disease medicine that serves as the basis for a partnership between Roivant Sciences and Pfizer met high expectations for a Phase 2 clinical trial data released Wednesday.
In a clinical study of 245 volunteers, the drug, called RVT-3101, helped 32% of trial participants with ulcerative colitis go into remission, compared to 12% in the placebo group. The drug also performed well at the dose Roivant and Pfizer plan to use in Phase 3 testing.
The treatment works by targeting a protein called TL1A that’s linked to inflammation and tissue scarring. It’s the same strategy that competitor Prometheus Biosciences is employing. That company’s drug performed better than expected in Phase 2 data released last month, helping nearly 27% of trial participants enter remission.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.